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ABSTRACT
Introduction: To explore how adaptive choi-
ce-based conjoint (ACBC) analysis could con-
tribute to shared decision-making in the
treatment of individual patients with
osteoarthritis (OA).
Methods: In-depth case study of three individ-
uals randomly selected from patients with OA
participating in an ACBC analysis exercise. Ele-
ven members of a research users’ group partici-
pated in developing an ACBC task on
medication preferences for OA. Individual
medication priorities are illustrated by the
detailed analysis of ACBC output from three
randomly selected patients from the main
sample.
Results: The case study analysis illustrates
individual preferences. Participant 1’s priority
was avoidance of the four high-risk side effects
of medication, which accounted for 90% of the
importance of all attributes, while the remain-
ing attributes (expected benefit; way of taking
medication; frequency; availability) accounted
only for 10% of the total influence. Participant
3 was similar to participant 1 but would accept a
high risk of one of the side effects if the medi-
cation were available by prescription. In con-
trast, participant 2’s priority was the avoidance
of Internet purchase of medication; this attri-
bute (availability) accounted for 52% of the
importance of all attributes.
Conclusions: Individual patients have prefer-
ences that likely lead to different medication
choices. ACBC has the potential as a tool for
physicians to identify individual patient pref-
erences as a practical basis for concordant pre-
scribing for OA in clinical practice. Future
research needs to establish whether accurate
knowledge of individual patient preferences for
treatment attributes and levels translates into
concordant behavior in clinical practice.
Keywords: ACBC analysis; Adaptive
choice-based conjoint analysis; Osteoarthritis;
Patient preferences; Pharmaceutical treatment
INTRODUCTION
National and international guidelines for the
management of patients with osteoarthritis
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(OA) conclude that prescribed medications,
notably nonsteroidal anti-inflammatory drugs
(NSAIDS), have an important role to play,
alongside non-pharmacological interventions
[1, 2], in the long-term relief of pain and
improvement in activity of daily living. How-
ever, there is evidence that many patients with
long-term conditions such as OA do not utilize,
or continue with, prescribed medication.
Non-adherence may often be intentional and
may reflect rational decisions by patients related
to factors other than the efficacy of the medi-
cine for their particular condition, such as per-
ceived side effects, inconvenience of dosage
times, and the mode of drug delivery [3]. From a
health care policy perspective, there are con-
cerns that prescribing should be evidence-based
[4], whilst acknowledging patient concerns
[5, 6]. Concordance has been defined as
‘‘agreement between the patient and healthcare
professional, reached after negotiation, that
respects the beliefs and wishes of the patient in
determining whether, when and how their
medicine is taken, and in which the primacy of
the patient’s decision is recognized’’ [6].
The challenge is how to translate the concept
of concordance into practical and meaningful
activity in the clinical situation. One specific
problem is how to elicit information about
patient preferences in a format that can inform
the clinician and underpin joint decisions, with
evidence suggesting that the amount of infor-
mation being shared in a usual consultation is
often misjudged by both doctors and their
patients [7]. A second problem is that while
some interventions to improve concordance
have been developed, they have not had a clear
impact on long-term patterns of medication use
[8].
To date, attempts to improve concordance
have often focused on the conversation that
takes place during a consultation. An alterna-
tive approach is to improve the availability of
relevant information in the consultation by
applying formal methods of decision analysis to
each individual patient in the clinical situation.
There is evidence that patients can benefit from
the use of decision support systems, but their
complexity and the resulting increase in work-
load and interruption with the natural
exchange of a consultation are seen as barriers
to their use by clinicians [9].
A different way to gather and present infor-
mation from patients is to present scenarios
containing different medication attributes. We
have recently completed a feasibility study
using adaptive choice-based conjoint analysis
(ACBC). ACBC combines features of two earlier
methods: adaptive conjoint analysis (ACA) and
choice-based conjoint (CBC) analysis. ACA
allows participants to develop their preferences
for sets of attribute configurations interactively
[10], while CBC asks participants to choose their
preference between presented sets of treatment
attributes [10].
In the ACBC study reported here, partici-
pants with OA were presented with scenarios on
a computer comprising eight different medica-
tion attributes and their task was to choose
which scenario was preferable. Successive sce-
narios adapted to participants’ prior responses.
We have established the feasibility, practicality,
and patient acceptability of this method among
a group of older patients with OA [11]. All stages
of the study were informed by the International
Society for Pharmacoeconomics and Outcomes
Research (ISPOR) guidelines for the conduct of
conjoint analysis [12].
The aim of the current study was to investi-
gate the potential of ACBC as an approach to
supporting shared decision-making with indi-
vidual patients in clinical practice.
METHODS
Our design was a detailed case study of the
ACBC output of three individual patients ran-
domly selected from a sample of patients with
OA who participated in an ACBC exercise.
Participants
All participants in the ACBC project were
members of the osteoarthritis research users’
group (RUG), part of the wider public and
patient involvement initiative in the Arthritis
Research UK Primary Care Centre at Keele
University, UK. Eleven RUG members with
osteoarthritis and reporting one or more of hip,
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knee, hand, and foot joint pain over the previ-
ous 12 months and aged over 50 years (seven
females and four males) were invited to partic-
ipate. None of the 11 participants were involved
in any previous ACBC study and had not taken
part in developing the questionnaire. Three
participants—indicated as participants 1, 2, and
3—were randomly selected for detailed discus-
sion in this paper.
Ethical Statement
All participants in the ACBC project were
members of the extended Patient and Public
Involvement group of the Arthritis Research UK
Primary Care Centre at Keele University. These
members all sign an agreement that provides
general consent to use their expertise in the
development of research. The study complied
with Keele University guidelines for the storage
of sensitive and confidential data on laptops.
Attributes and Levels
Defining attributes and levels is the most fun-
damental and critical aspect of designing a good
conjoint analysis study [13]. Choice-based tasks
such as ACBC define scenarios on the basis of
pre-defined ‘attributes’ (for example in medica-
tion studies, characteristics such as route of
administration) and ‘levels’ of the attribute (for
example, oral and topical as levels of the ‘‘route
of administration’’ attribute). When selecting
the attributes, it is important that the ones
included in the conjoint analysis task are factors
that influence patient preference regarding
pharmaceutical treatment of OA and are easy
for the respondents to understand. The ratio-
nale and justification behind the inclusion of
attributes were based upon: a full systematic
search to identify the attributes used in similar
studies, an ACBC feasibility study [11], and a
recommendation from an earlier study that
more side-effect attributes should be included
than in previous choice experiments relating to
NSAIDS for osteoarthritis [14]. In general,
researchers should select attributes and levels
that are realistic and credible to respondents
[15]. Therefore, the wording and terminology
used in all attributes and levels were based on
RUG recommendations and suggestions, for
example, RUG members suggested using ‘‘no
risk to high risk’’ instead of percentages to rep-
resent risk of side effects. Furthermore, RUG
members suggested using 25, 50, and 75% to
represent the benefit levels; the rationale was
that patients would not expect 100% benefit
and they would not take the medication if it has
0% benefit. The attributes and levels are shown
in Table 1. No RUG members who participated
in the development of attributes and levels
participated in completing the final ACBC
questionnaire.
ACBC Task
As previously described [11], participants were
invited individually to complete the ACBC task
on a computer in the computer laboratory at
Keele University. The computer-based interac-
tive ACBC task was created using Sawtooth
Software Inc. (SSI) survey platform (8.0.2) [16].
The first screen was an introduction explaining
the task. This was followed by questions on
demography and the respondents’ health. The
main task consisted of three stages.
Stage 1: Build your own (BYO) configuration
section. This task includes one BYO question
that introduces all attributes and levels and asks
the respondents to indicate the preferred level
for each attribute. The software then generates
scenarios based on these attributes and levels.
An example of a BYO question is shown in
Fig. 1.
Stage 2: Screening section, which includes
three different types of questions:
(a) ‘‘Screening’’ Questions Based on each respon-
dent’s answers in stage 1, the software
creates a pool of hypothetical scenarios
that includes every attribute level but
focuses around the respondent’s preferred
levels. These scenarios are customized indi-
vidually and are generated during the task
for each respondent. According to the
software guidelines, and based on the
number of attributes and levels included
in this study, we instructed the software to
generate seven pages with four screening
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questions on each page for each respon-
dent. In each screen, the respondents were
shown four different scenarios and asked to
indicate whether they would consider each
one as ‘‘a possibility’’ or ‘‘won’t work for
me’’. At this stage, respondents are not
asked to make final choices, as the software
is trying to identify the most and least
important level for each attribute. An
example of a screening task is shown in
Fig. 2.
(b) ‘‘Unacceptable’’ Questions Here, respondents
indicate if they are avoiding a specific level
of some attributes. After the ‘‘screening
questions’’, the software evaluates whether
the respondent was using non-compen-
satory screening rules (i.e., if the respon-
dent was systematically avoiding one or
more specific levels). All levels that could
have been possibly avoided are then pre-
sented to the respondents in the ‘‘unac-
ceptable question’’ format and they are
asked to indicate if they were avoiding one
of these levels or they wish to opt-out; i.e.,
‘‘none of the listed levels is totally unac-
ceptable’’. The selected level will then be
eliminated from the following screening
questions. According to the software guide-
lines and based on the number of attri-
butes and levels included in this study, we
instructed the software to generate a max-
imum of four unacceptable questions for
each respondent. The number of unaccept-
able questions varies between respondents
based on the respondents’ non-compen-
satory screening rules. An example of the
unacceptable question is shown in Fig. 3.
(c) ‘‘Must Have’’ Questions Here, respondents
indicate if they are interested in only one
level of some attributes. After at least two
‘‘unacceptable’’ questions, the software
scans and evaluates previous answers to
see if the respondent expressed interest in
only one level of some attributes. These
levels are then presented to the respondent
in ‘‘must have’’ question format. If the
respondent chooses a specific level in the
‘‘must have’’ question, the software will
eliminate all other levels of the same
attribute and the respondent will only
have this one level in all subsequent ques-
tions. Thus, the ‘‘must have’’ questions are
very significant and the software does not
Table 1 Adaptive choice-based conjoint (ACBC) attri-
butes and levels
Attribute Levels
Availability Prescription drug
Over-the-counter
drug
Internet-purchase
drug
Route of administration Cream/gel
Oral
Frequency Once a day
Twice a day
3–4 times a day
As needed
Expected percentage of benefit Expect 25% benefit
Expect 50% benefit
Expect 75% benefit
Risk of gastric ulcer No risk
Low risk
Moderate risk
High risk
Risk of addiction No risk
Low risk
Moderate risk
High risk
Risk of kidney and liver
impairment
No risk
Low risk
Moderate risk
High risk
Risk of heart attacks and strokes No risk
Low risk
Moderate risk
High risk
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Fig. 1 An example of a ‘‘BYO question’’ from the ACBC task
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present them to all respondents. The soft-
ware produces the ‘‘must have’’ question
when it picks up that one level of a
particular attribute was constantly selected
by the respondent. However, an opt-out
answer is always provided in both ‘‘unac-
ceptable’’ and ‘‘must have’’ questions. The
view of the ‘‘must have’’ question is very
similar to the ‘‘unacceptable’’ question.
Stage 3: Choice tasks section Finally, the respon-
dents are shown a series of choice tasks, pre-
senting scenarios that have the remaining levels
in groups of three scenarios. These scenarios
consist of the levels that the respondent marked
as possibilities and conform to the must have/
unacceptable rules. The chosen scenario in the
first choice question will then compete in the
next question with more scenarios until the
software identifies the preferred scenario of the
respondent. The number of choice tasks varies
between respondents based on the respondents’
determination and selection of particular levels
of particular attributes. An example of a choice
task is shown in Fig. 4.
Data Analysis
Regression techniques are used to analyze the
responses for all types of conjoint analysis. The
ACBC questionnaire uses two types of regres-
sion: hierarchical Bayes (HB) and monotone
regression. Generally, it is recommended to use
HB even with a small sample size. However,
ACBC’s predictions from monotone regression
are as good as those from HB estimation and
when strictly individual estimation is required,
monotone regression produces results that are
applicable, usable, and uninfluenced by the
group average [17]. Therefore, monotone
regression was used to analyze individual
respondent results. The ACBC software has a
built-in monotone regression analysis. The
results of the monotone regression are pre-
sented as the relative importance of each attri-
bute to the individual patient. The relative
importance of the attributes is a calculation for
each attribute as to the weight that the indi-
vidual places on it compared with the other
Fig. 2 An example of a ‘‘screening question’’ from the ACBC task
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seven attributes that the individual has been
assessing in the scenarios during the task. The
relative importance figures for each of the eight
attributes add up to 100% for that individual
[18]. The term ‘importance’ may be misinter-
preted as a positive value. For example, 20%
relative importance for an attribute may not
necessarily mean that this attribute is impor-
tant. It could mean that it is the least important
attribute if all other attributes within the con-
joint task have higher relative importance.
Therefore, the relative importance value for one
attribute should be interpreted in the context of
others within the conjoint task.
Although the relative importance (attribute
score) indicates which attributes are important
to a participant, it does not provide an indica-
tion of which aspects (level) of the attribute an
individual regards as the most and least impor-
tant. For example, the frequency of taking
medicine may be an important attribute, but
the relative importance score does not provide
information about which level the patient
would opt for, e.g., one a day, twice a day, 3–4
times a day, or as needed. Such information on
the levels is provided by the utility values for
each level of each attribute. The utilities for all
levels were calculated using the monotone
regression [19]. Generally, conjoint analysis
assumes that respondents place specific value
(utility) on each level of an attribute. In ACBC
monotone regression, the calculation of the
utilities differs from traditional CBC. In ACBC
regression, the utility score of each level is
arbitrary (as given by the software), and utilities
are interval data scaled to an arbitrary additive
constant within each attribute [18]. Thus, the
relative importance value is not sensitive to the
number value of the utilities, but to the overall
scaling of the levels. The utility for each level is
a number that represents the weight that a
respondent puts on that particular level in the
context of other levels within the same attri-
bute. The level with the highest utility in each
attribute is the most favorable, and the utilities
of all levels in each attribute are scaled to sum to
0. Unlike HB, which uses the logit rule to esti-
mate utilities, the utilities in the monotone
regression are ordinal, representing the order of
the levels only [20]. The utility value of one
level cannot therefore be arithmetically com-
pared with the value of another level in another
attribute or the same level in another individual
participant. These values have a meaning
within each attribute but cannot be compared
across several attributes and the intervals
Fig. 3 An example of
an ‘‘unacceptable ques-
tion’’ from the ACBC
task
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between the values of the utilities are only
comparable within each attribute. Therefore,
the utilities for each individual participant were
standardized to have a mean of zero and a
standard deviation of 1. We created standard-
ized values (z-scores) using SPSS. By standard-
izing the attribute level values, it is possible to
examine the trade-offs between the levels of
different attributes that a participant is willing
to make. For example, the analysis will reveal if
a participant is willing to trade-off a high risk of
heart attack from treatment for his or her OA if
offered a 50% expected benefit compared, say,
to a 25% expected benefit of the treatment.
RESULTS
Participants’ Characteristics
Participants’ characteristics in the main ACBC
sample are shown in Table 2. The majority of
respondents were aged 60–69 and most had OA
for more than 5 years. Most patients reported
that pain interfered moderately or extremely
with daily life.
Attributes-Relative Importance Scores
Table 3 shows the percentage relative impor-
tance scores for all ACBC participants. Each
participant’s profile can be compared to the
‘‘group average’’ column in Table 3. The three
selected detailed participant profiles are labeled
as participants 1, 2, and 3.
For participant 1, four attributes contribute
over 90% of the total relative importance: ‘‘risk
of kidney/liver side effects’’, ‘‘risk of heart
attacks/strokes’’, ‘‘risk of addiction’’ and ‘‘risk of
stomach side effects’’. Four attributes are of rel-
atively negligible importance: ‘‘availability’’,
‘‘frequency of taking’’, ‘‘way of taking’’ and
‘‘expected benefit’’. For participant 1, avoidance
of risk emerges as the dominant factor in med-
ication preference.
For participant 2, the ‘‘availability’’ attribute
has a relative importance score of 52%. Three of
the ‘‘risk’’ attributes have values of around 10%,
while ‘‘frequency of taking’’, ‘‘way of taking’’,
‘‘expected benefit’’ and ‘‘risk of stomach side
effects’’ are of relatively little importance to
participant 2. For participant 2 therefore,
Fig. 4 An example of a ‘‘choice question’’ from the ACBC task
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‘‘availability’’ emerges as the dominant factor in
medication preference.
For participant 3, four attributes are impor-
tant: ‘‘risk of kidney/liver side effects’’, ‘‘risk of
heart attacks/strokes’’, ‘‘risk of addiction’’ and
‘‘availability’’. ‘‘Frequency of taking’’, ‘‘way of
taking’’ and ‘‘expected benefit’’ are of relatively
little importance to this participant, for whom
avoidance of risk and ‘‘availability’’ emerge as
the dominant factors in medication preference.
This participant is similar to participant 1, with
the exception that ‘‘risk of stomach side effects’’
is less important and ‘‘availability’’ is more
important (Table 3).
Attribute Levels
The attribute level data shown in Figs. 1, 2, and
3 indicate the specific preferences of each
participant within each attribute. The stan-
dardized format allows us to identify potential
trade-offs between the levels of different attri-
butes that the patient is willing to make in
choosing the preferred medication format.
For participant 1 (Fig. 5), the main con-
cerns are avoidance of all high-risk side effects
(kidney/liver impairment; stomach ulcer;
heart attacks/stroke; and addiction). The
standardized scores suggest that if this indi-
vidual had to accept one type of high-risk side
effect, there would be a slight preference to
accept a high risk of heart attack/stroke rather
than of kidney/liver side effects, stomach side
effect or addiction. The remaining attributes
and their levels (expected benefit, way of tak-
ing medication, frequency, and availability)
have, in comparison, little influence on the
choice.
For participant 2 (Fig. 6), the dominant
concern is to avoid internet purchased drugs
and conversely to be able to get medication over
the counter. The standardized scores indicate
that this individual is willing to accept high
risks of gastric ulcer, of addiction, of kidney/
liver impairment and of heart attack or stroke in
order to be able to get medicine over the
counter (as opposed to on prescription or over
the Internet). If the drug were only available on
prescription, this individual would not accept
any of these side effects at the ‘‘high’’ level but
would accept low risk of all the side effects.
These results may indicate that the participant
believes that over-the-counter medicines are
unlikely to have high risk of side effects.
Participant 3 (Fig. 7) is somewhat similar to
participant 1 in seeking to avoid side effects.
However, for this participant, availability of
medicine via prescription is an important attri-
bute level. The results indicate that if the drug
were available on prescription, this individual
would accept a high risk of one of the side
effects, but any combination of high-risk side
effects would outweigh the utility of obtaining
the drug on prescription. These results may
indicate that the participant places a high value
on having a medicine prescribed by a doctor (as
opposed to participant 2, who favors
over-the-counter medication).
Table 2 Participant characteristics
Characteristic Frequency Percent
Age groups
50–59 1 9.1
60–69 7 63.6
70–79 1 9.1
Over 79 2 18.2
Gender
Male 4 36.4
Female 7 63.6
Number of years suffering from osteoarthritis
1–2 years 1 9.1
3–4 years 2 18.2
5–10 years 4 36.4
More than 10 years 4 36.4
How much does pain interfere with normal life?
A little bit 2 18.2
Moderately 5 45.5
Quite a bit 2 18.2
Extremely 2 18.2
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DISCUSSION
TheACBC task used in this studywith participants
withOA is able to elicit specific patient preferences
aboutmedication in around 20 min [11].We have
confirmed thatACBChas the potential to consider
a wider range of treatment permutations than
previous studies (see Table 4). The ACBC task was
also able to distinguish between individuals with
OA who have varying and contrasting preferences
with respect to one of the most common and
guideline-recommended treatments for the
long-term management of symptoms and disabil-
ity, namely NSAIDs [1].
It is becoming clear that concordance
requires methods for transforming complex
information into a format that doctors and
participants can readily and rapidly view. In
2006, the average duration of GP consultation
in England was 12 min [24]. Patients are
increasingly turning to the Internet to get
information on medicines [25] and health care
professionals are using a range of information
technologies [26].
While empirical evidence indicates that
decision support systems can improve adher-
ence [27], the ACBC method has not yet been
used in clinical practice, although the possibil-
ity of using conjoint analysis has been advo-
cated [28].
The implication of the findings presented here
is that, in terms of both attributes and attribute
levels, individual patients have preferences that
are likely to lead to different medication choices.
We reported in a previous paper that ten out of
the total 11 participants confirmed that the
results of the task reflected their own preferences
and one participant was not sure that the pre-
diction of the attribute with the highest relative
importance was accurate, but agreed with the
remaining results [11]. Given that these prefer-
ences could be elicited in clinical practice and
made available to both clinicians and patients as
part of their consultation together, the profiles
presented here highlight the potential for an
ACBC task to be used for such consultations and
to improve concordance. However, our study has
not investigated the usefulness and impact of the
task in such a clinical setting. It remains to be
determined whether accurate knowledge of indi-
vidual patient preferences for treatment attributes
and their levels translates into concordant
behavior in clinical practice.
Another possible limitation is that the
majority (four out of eight) of attributes inclu-
ded in the ACBC questionnaire were about
medication side effects, which may undervalue
the importance of medication benefits. Fur-
thermore, the numbers of levels in each attri-
bute were different. For example, ‘way of taking
Table 3 Relative importance values for participants’ attributes (expressed as percentages)
Attributes Participant ID Group
mean1 2 3 4 5 6 7 8 9 10 11
1 Availability (source): 3 levels 3 52 22 3 11 30 6 0 22 17 11 13
2 Frequency of taking: 3 levels 5 3 5 0 4 11 10 2 22 10 2 8
3 Way of taking the medication: 2 levels 0 5 0 26 14 12 2 3 0 6 1 8
4 Expected benefit: 3 levels 3 5 2 19 6 18 5 17 8 4 7 11
5 Risk of addiction: 4 levels 25 12 19 6 7 0 19 19 10 4 7 9
6 Risk of heart attacks and strokes: 4 levels 21 10 21 15 20 9 23 19 12 16 25 17
7 Risk of kidney and liver side effects: 4 levels 25 9 23 24 18 6 19 21 21 15 27 19
8 Risk of stomach side effects: 4 levels 19 3 9 5 20 14 15 19 5 28 20 16
Total 100 100 100 100 100 100 100 100 100 100 100 100
The three participants considered in the main text are participants 1, 2, and 3
Rheumatol Ther
the medication’ included two levels, while side
effect attributes included four levels each.
Generally, in conjoint analysis, attributes with a
greater number of levels are found to be more
important, and this should be borne in mind
when interpreting our results.
One question is whether people are con-
sciously aware of their medication preferences.
Consumer psychologists have shown that
people’s behavior in, for example, supermar-
kets is to a considerable extent governed by
factors of which they have no conscious
knowledge. For example, slow music played in
supermarkets is associated with longer visits
than fast music [29]. It is known that ‘‘even
goal-directed behavior often takes place
Fig. 5 Attribute
levels for participant 1
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outside conscious awareness and that goals
can be automatically activated by a multitude
of environmental cues’’ [30]. People’s attitudes
to taking medicines are influenced by many
factors (including those reported here). While
the current study does not consider the rea-
sons for people’s preferences, its starting point
is that current preferences of patients with OA
are potentially important to elicit and
consider as part of promoting concordance
with NSAID treatment. ACBC makes explicit
the relative importance of a range of factors
and, as reported by us previously, participants
thought that the ACBC task was responsive
and helped in making decision about medici-
nes [11].
As Coulter [31] has observed, the rhetoric of
patient-centered medicine is not always
Fig. 6 Attribute
levels for participant 2
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matched by its practice. In the field of OA,
achieving patient-centered medicine is ham-
pered by the paucity of studies that have
explored medication-taking decisions [32]. Our
case studies explored a wider range of attributes
and levels than have hitherto been studied in
relation to OA medication. ACBC makes, at
least to some extent, possibly unconscious
decisions explicit and allows the patient some
insight into normally hidden values and pref-
erences. By using a case study approach, this
study highlights individual profiles and how
these could form the basis for concordant
prescribing.
Fig. 7 Attribute
levels for participant 3
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CONCLUSIONS
In conclusion, this study has shown that indi-
vidual patients have preferences that are likely
to lead to different medication choices. ACBC
has the potential to identify individual prefer-
ences as a practical basis for concordant pre-
scribing for osteoarthritis in clinical practice.
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Table 4 Characteristics of discrete choice and conjoint studies
Attributes Number of attribute
x level combinations
Experimental
scenariosa
Scenarios Methodb Study
6 attributes: 4 at 2 levels, 1 at 3
levels, 1 at 4 levels
192 16 Pre-selected DCE
(choice)
Ryan et al.
[21]
6 attributes: 3 at 2 levels, 3 at 4 levels 512 16 Pre-selected DCE
(choice)
Seston
et al.
[22]
7 attributes: 1 at 2 levels, 1 at 3
levels, 3 at 4 levels, 2 at 5 levels
9600 20–30 Adapt with
responses
ACA
(mainly
ranking)
Fraenkel
et al.
[23]
8 attributes: 1 at 2 levels, 2 at 3
levels, 5 at 4 levels
18,432 20–30 Adapt with
responses
ACBC
(mainly
choice)
Current
study
a Number of scenarios is approximate for ACA/ACBC, as there are a number of types of questions
b
DCE discrete choice experiment, ACA adaptive conjoint analysis, ACBC adaptive choice-based conjoint analysis
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noncommercial use, distribution, and repro-
duction in any medium, provided you give
appropriate credit to the original author(s) and
the source, provide a link to the Creative
Commons license, and indicate if changes were
made.
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